Article Text

Download PDFPDF
Patterns of Recurrence and Role of Pelvic Radiotherapy in Ovarian Clear Cell Adenocarcinoma
  1. Bryan D. Macrie, MD*,
  2. Jonathan B. Strauss, MD*,
  3. Irene B. Helenowski, PhD,,
  4. Alfred Rademaker, PhD,,
  5. Julian C. Schink, MD§,
  6. John R. Lurain, MD§ and
  7. William Small, MD
  1. *Department of Radiation Oncology and
  2. Department of Preventive Medicine, Division of Biostatistics, Northwestern University Feinberg School of Medicine;
  3. Robert H. Lurie Comprehensive Cancer Center and
  4. §Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine;
  5. Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago.
  1. Address correspondence and reprint requests to William Small Jr, MD, Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Cardinal Bernardin Cancer Center, 2160 S 1st Ave, Maguire Center, Rm 2932, Maywood, IL. E-mail: wmsmall@lumc.edu.

Abstract

Objective(s) The aims of this study were to analyze patterns of recurrence in patients with ovarian clear cell adenocarcinoma (CCA) and to evaluate the role of pelvic radiotherapy (RT).

Methods and Materials All patients with ovarian CCA treated at a single institution between 1989 and 2012 were identified, and their medical records were reviewed. Eligibility criteria included histologic diagnosis of pure CCA of the ovary, surgical staging for International Federation of Gynecology and Obstetrics stage I-to-IIIC disease, and adjuvant or neoadjuvant chemotherapy. Selected end points were 3-, 5-, and 8-year cumulative incidence of pelvic recurrence (CIPR).

Results Fifty-six patients met eligibility criteria. Most received intravenous carboplatin and paclitaxel for a median of 6 cycles. Six patients (10.7%) received pelvic RT, and 50 (89.3%) did not. Pelvic RT patients had stage I-to-IIC disease. Median follow-up was 39 months (range, 1–69 months). For the group as a whole, 14 patients (25%) had initial disease recurrence involving the pelvis, whereas 6 (10.7%) had first recurrence outside the pelvis. Three-, 5- and 8-year CIPR were 28.2%, 38.5%, and 43.2%, respectively. There was no significant difference in 3-, 5-, or 8-year CIPR between the group of patients receiving RT (20%, 20%, and 20%) and a group of patients with stages I to IIC who did not receive RT (9.9%, 22.4%, and 30.2%), P = 0.22. During RT, patients developed mild grade 1-to-2 side effects. After RT, 1 patient developed lower extremity lymphedema with recurrent cellulitis. One patient who developed small bowel obstruction before RT developed small bowel radiation enteritis and obstruction after RT, ultimately requiring surgical intervention.

Conclusions These findings suggest that ovarian CCA exhibits a propensity for pelvic recurrence after surgery and chemotherapy. RT, a local treatment that can effectively sterilize microscopic tumor cells, may benefit patients with this disease. Prospective studies with sufficient statistical power are warranted to further evaluate the role of RT.

  • Clear cell ovarian carcinoma
  • Adjuvant radiotherapy
  • Pelvic radiotherapy
  • Recurrence patterns

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.